Results of General Meeting

MGC Pharmaceuticals Limited

18 March 2024

 

MGC Pharmaceuticals Ltd

Results of General Meeting

18 March 2024

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the voting results from the Company's General Meeting of shareholders, held today Monday, 18 March 2024.

The Company advises that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the results can be found in the following URL:
https://www.investi.com.au/api/announcements/mxc/b11d4b33-9bd.pdf

As a result of Resolution 1 having been passed at the meeting, shareholders have granted approval for the Company to change its name to Argent Biopharma Ltd, reflecting the final step in a comprehensive restructuring.

The Company is currently in the process of notifying the Australian Securities and Investments Commission (ASIC) of the change of name and will update shareholders with additional details prior to the effective date.

-Ends-

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd              Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma

 

END